Replies to post #166603 on Biotech Values

[biomaven0]

>SCTPF

whether the MOA between the two approaches is really all that different

As I understand it, it's pretty analogous to the Enbrel/Remicade story. Basically two slightly different ways to skin the same cat. But when you are trying to modulate the immune system, small differences in approach can sometimes produce big differences in safety and efficacy.

Here's the SCTPF patent:

http://patentscope.wipo.int/search/en/WO2010130053

I really haven't looked at the Stanford patent suite - I am prepared to believe it is very broad though.

Peter